Physician profile
Simon E Carlo
NPI 1023139896
$4,389.19
in general payments reported to CMS, 2019-2025
6 companies · $4,018 in 2025
The $4,018 reported for 2025 was more than what 88% of Clinical Molecular Genetics providers received nationally (typical 2025 total: $117).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $20.76 · 2021: $53.74 · 2023: $30.56 · 2024: $122 · 2025: $4,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,640 · Food and Beverage: $531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,640.00 |
| Food and Beverage | $530.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $4,168.39 | 2019-2025 | |
| Pfizer Pharmaceuticals LLC | $107.07 | 2019 | |
| Biomarin Pharmaceutical INC. | $53.74 | 2021 | |
| Chiesi USA, INC. | $21.76 | 2025 | Elfabrio |
| Takeda Pharmaceuticals U.S.A., INC. | $20.76 | 2020 | |
| Amicus Therapeutics, INC. | $17.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Carlo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.